Advertisement

AAPS PharmSciTech

, 20:159 | Cite as

Evaluation of Hydrogenated Soybean Phosphatidylcholine Matrices Prepared by Hot Melt Extrusion for Oral Controlled Delivery of Water-Soluble Drugs

  • Marina Kolbina
  • Adrian Schulte
  • Peter van Hoogevest
  • Martin KörberEmail author
  • Roland Bodmeier
Research Article Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery
Part of the following topical collections:
  1. Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery

Abstract

The aims of this study were to prepare hydrogenated soybean phosphatidylcholine (HSPC) matrices by hot melt extrusion and to evaluate resulting matrix potential to extend drug release in regard to drug loading and solubility for oral drug delivery of water-soluble drugs. The liquid crystalline nature of HSPC powder allowed its extrusion at 120°C, which was below its capillary melting point. Model drugs with a wide range of water solubilities (8, 20 and 240 mg/mL) and melting temperatures (160–270°C) were used. Extrudates with up to 70% drug loading were prepared at temperatures below the drugs’ melting points. The original crystalline state of the drugs remained unchanged through the process as confirmed by XRPD and hot-stage microscopy. The time to achieve 80% release (t80) from extrudates with 50% drug loading was 3, 8 and 18 h for diprophylline, caffeine and theophylline, respectively. The effect of matrix preparation method (extrusion vs. compression) on drug release was evaluated. For non-eroding formulations, the drug release retarding properties of the HSPC matrix were mostly not influenced by the preparation method. However, with increasing drug loadings, compressed tablets eroded significantly more than extruded matrices, resulting in 2 to 11 times faster drug release. There were no signs of erosion observed in extrudates with different drugs up to 70% loadings. The mechanical robustness of HSPC extrudates was attributed to the formation of a skin-core structure and was identified as the main reason for the drug release controlling potential of the HSPC matrices produced by hot melt extrusion.

KEY WORDS

HSPC hot melt extrusion extended release matrix mathematical modelling oral controlled release 

Notes

Acknowledgements

This work was supported by Phospholipid Research Center (Heidelberg, Germany). The authors thank Eva Hepke (Technische Universität Berlin) for technical support with XRPD measurements.

Supplementary material

12249_2019_1366_MOESM1_ESM.docx (3.2 mb)
ESM 1 (DOCX 3231 kb)

References

  1. 1.
    Grund J, Koerber M, Walther M, Bodmeier R. The effect of polymer properties on direct compression and drug release from water-insoluble controlled release matrix tablets. Int J Pharm. 2014;469(1):94–101.CrossRefGoogle Scholar
  2. 2.
    Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release. 2011;154(1):2–19.CrossRefGoogle Scholar
  3. 3.
    Roberts M, Pulcini L, Mostafa S, Cuppok-Rosiaux Y, Marchaud D. Preparation and characterization of Compritol 888 ATO matrix tablets for the sustained release of diclofenac sodium. Pharm Dev Technol. 2015;20(4):507–12.CrossRefGoogle Scholar
  4. 4.
    Kolbina M, Bodmeier R, Körber M. Saturated phosphatidylcholine as matrix former for oral extended release dosage forms. Eur J Pharm Sci. 2017;108:86–92.CrossRefGoogle Scholar
  5. 5.
    van Hoogevest P. Review—an update on the use of oral phospholipid excipients. Eur J Pharm Sci. 2017;108:1–12.CrossRefGoogle Scholar
  6. 6.
    Crowley MM, Schroeder B, Fredersdorf A, Obara S, Talarico M, Kucera S, et al. Physicochemical properties and mechanism of drug release from ethyl cellulose matrix tablets prepared by direct compression and hot-melt extrusion. Int J Pharm. 2004;269(2):509–22.CrossRefGoogle Scholar
  7. 7.
    Grehan L, Killion JA, Devine DM, Kenny EK, Devery S, Higginbotham CL, et al. The development of hot melt extruded biocompatible controlled release drug delivery devices. Int J Polym Mater Polym Biomater. 2014;63(9):476–85.CrossRefGoogle Scholar
  8. 8.
    Kipping T, Rein H. Continuous production of controlled release dosage forms based on hot-melt extruded gum arabic: formulation development, in vitro characterization and evaluation of potential application fields. Int J Pharm. 2016;497(1–2):36–53.CrossRefGoogle Scholar
  9. 9.
    Kallakunta VR, Tiwari R, Sarabu S, Bandari S, Repka MA. Effect of formulation and process variables on lipid based sustained release tablets via continuous twin screw granulation: a comparative study. Eur J Pharm Sci. 2018;121:126–38.CrossRefGoogle Scholar
  10. 10.
    Siepmann F, Muschert S, Flament MP, Leterme P, Gayot A, Siepmann J. Controlled drug release from Gelucire-based matrix pellets: experiment and theory. Int J Pharm. 2006;317(2):136–43.CrossRefGoogle Scholar
  11. 11.
    Güres S, Siepmann F, Siepmann J, Kleinebudde P. Drug release from extruded solid lipid matrices: theoretical predictions and independent experiments. Eur J Pharm Biopharm. 2012;80(1):122–9.CrossRefGoogle Scholar
  12. 12.
    Sato H, Miyagawa Y, Okabe T, Miyajima M, Sunada H. Dissolution mechanism of diclofenac sodium from wax matrix granules. J Pharm Sci. 1997;86(8):929–34.CrossRefGoogle Scholar
  13. 13.
    De Brabander C, Vervaet C, Fiermans L, Remon JP. Matrix mini-tablets based on starch/microcrystalline wax mixtures. Int J Pharm. 2000;199(2):195–203.CrossRefGoogle Scholar
  14. 14.
    Liu J, Zhang F, McGinity JW. Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion. Eur J Pharm Biopharm. 2001;52(2):181–90.CrossRefGoogle Scholar
  15. 15.
    Roblegg E, Jäger E, Hodzic A, Koscher G, Mohr S, Zimmer A, et al. Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion. Eur J Pharm Biopharm. 2011;79(3):635–45.CrossRefGoogle Scholar
  16. 16.
    Laukamp EJ, Vynckier A-K, Voorspoels J, Thommes M, Breitkreutz J. Development of sustained and dual drug release co-extrusion formulations for individual dosing. Eur J Pharm Biopharm. 2015;89:357–64.CrossRefGoogle Scholar
  17. 17.
    Hasa D, Perissutti B, Grassi M, Zacchigna M, Pagotto M, Lenaz D, et al. Melt extruded helical waxy matrices as a new sustained drug delivery system. Eur J Pharm Biopharm. 2011;79(3):592–600.CrossRefGoogle Scholar
  18. 18.
    Vithani K, Cuppok Y, Mostafa S, Slipper IJ, Snowden MJ, Douroumis D. Diclofenac sodium sustained release hot melt extruded lipid matrices. Pharm Dev Technol. 2014;19(5):531–8.CrossRefGoogle Scholar
  19. 19.
    Monteyne T, Adriaensens P, Brouckaert D, Remon J-P, Vervaet C, De Beer T. Stearic acid and high molecular weight PEO as matrix for the highly water soluble metoprolol tartrate in continuous twin-screw melt granulation. Int J. 2016;512(1):158–67.Google Scholar
  20. 20.
    Vaingankar P, Amin P. Continuous melt granulation to develop high drug loaded sustained release tablet of metformin HCl. Asian J Pharm Sci. 2017;12(1):37–50.CrossRefGoogle Scholar
  21. 21.
    Nart V, Beringhs AO, França MT, de Espíndola B, Pezzini BR, Stulzer HK. Carnauba wax as a promising excipient in melt granulation targeting the preparation of mini-tablets for sustained release of highly soluble drugs. Mater Sci Eng C. 2017;70:250–7.CrossRefGoogle Scholar
  22. 22.
    Chapman D, Williams RM, Ladbrooke BD. Physical studies of phospholipids. VI. Thermotropic and lyotropic mesomorphism of some 1,2-diacyl-phosphatidylcholines (lecithins). Chem Phys Lipids. 1967;1(5):445–75.CrossRefGoogle Scholar
  23. 23.
    Ghalanbor Z, Körber M, Bodmeier R. Improved lysozyme stability and release properties of poly (lactide-co-glycolide) implants prepared by hot-melt extrusion. Pharm Res. 2010;27(2):371–9.CrossRefGoogle Scholar
  24. 24.
    Shah VP, Tsong Y, Sathe P, Liu J. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–96.CrossRefGoogle Scholar
  25. 25.
    Koynova R, Caffrey M. Phases and phase transitions of the phosphatidylcholines. Biochim Biophys Acta Rev Biomembr. 1998;1376(1):91–145.CrossRefGoogle Scholar
  26. 26.
    Chapman D. Liquid crystalline nature of phospholipids. In: Porter RS, Johnson JF, editors. Ordered Fluids and Liquid Crystals: American Chemical Society; 1967. p. 157–66.Google Scholar
  27. 27.
    Williams RM, Chapman D. Phospholipids, liquids crystals and cell membranes. Prog Chem Fats Other Lipids. 1971;11:1–79.CrossRefGoogle Scholar
  28. 28.
    Byrne P, Chapman D. Liquid crystalline nature of phospholipids. Nature. 1964;202(4936):987–8.CrossRefGoogle Scholar
  29. 29.
    Ladbrooke BD, Chapman D. Thermal analysis of lipids, proteins and biological membranes a review and summary of some recent studies. Chem Phys Lipids. 1969;3(4):304–56.CrossRefGoogle Scholar
  30. 30.
    Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1–12.CrossRefGoogle Scholar
  31. 31.
    Bravo-Osuna I, Ferrero C, Jiménez-Castellanos MR. Influence of moisture content on the mechanical properties of methyl methacrylate–starch copolymers. Eur J Pharm Biopharm. 2007;66(1):63–72.CrossRefGoogle Scholar
  32. 32.
    Massing U, Bauer-Brandl A. Tablet containing hydrogenated phospholipids. EP1952805A1, 2008.Google Scholar
  33. 33.
    Luzzati V, Gulik-Krzywicki T, Tardieu A. Polymorphism of lecithins. Nature. 1968;218(5146):1031–4.CrossRefGoogle Scholar
  34. 34.
    Vergnaud JM. Controlled drug release of oral dosage forms. Boca Raton: CRC Press; 1993.CrossRefGoogle Scholar
  35. 35.
    Guse C, Koennings S, Kreye F, Siepmann F, Goepferich A, Siepmann J. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. Int J Pharm. 2006;314(2):137–44.CrossRefGoogle Scholar
  36. 36.
    Siepmann J, Siepmann F. Mathematical modeling of drug release from lipid dosage forms. Int J Pharm. 2011;418(1):42–53.CrossRefGoogle Scholar
  37. 37.
    Grund J, Körber M, Bodmeier R. Predictability of drug release from water-insoluble polymeric matrix tablets. Eur J Pharm Biopharm. 2013;85(3 Pt A):650–5.CrossRefGoogle Scholar
  38. 38.
    Yang L, Fassihi R. Examination of drug solubility, polymer types, hydrodynamics and loading dose on drug release behavior from a triple-layer asymmetric configuration delivery system. Int J Pharm. 1997;155(2):219–29.CrossRefGoogle Scholar
  39. 39.
    Harland RS, Gazzaniga A, Sangalli ME, Colombo P, Peppas NA. Drug/polymer matrix swelling and dissolution. Pharm Res. 1988;05(8):488–94.CrossRefGoogle Scholar
  40. 40.
    Streubel A, Siepmann J, Dashevsky A, Bodmeier R. pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets. J Control Release. 2000;67(1):101–10.CrossRefGoogle Scholar
  41. 41.
    Ide Y, Ophir Z. Orientation development in thermotropic liquid crystal polymers. Polym Eng Sci. 1983;23(5):261–5.CrossRefGoogle Scholar
  42. 42.
    Weiss RA, Huh W, Nicolais L. Novel reinforced polymers based on blends of polystyrene and a thermotropic liquid crystalline polymer. Polym Eng Sci. 1987;27(9):684–91.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Marina Kolbina
    • 1
  • Adrian Schulte
    • 2
  • Peter van Hoogevest
    • 3
  • Martin Körber
    • 4
    Email author
  • Roland Bodmeier
    • 1
  1. 1.College of PharmacyFreie Universität BerlinBerlinGermany
  2. 2.Lipoid GmbHLudwigshafenGermany
  3. 3.Phospholipid Research CenterHeidelbergGermany
  4. 4.Pensatech Pharma GmbHBerlinGermany

Personalised recommendations